We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today
Read MoreHide Full Article
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $111.01, marking a -3.23% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.34%. Meanwhile, the Dow experienced a drop of 0.94%, and the technology-dominated Nasdaq saw an increase of 0.16%.
Shares of the kidney dialysis provider have depreciated by 1.67% over the course of the past month, underperforming the Medical sector's gain of 0.82%, and the S&P 500's gain of 1.19%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is expected to report EPS of $3.34, up 49.11% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 6.99% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $10.52 per share and a revenue of $13.55 billion, indicating changes of +8.68% and 0%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, DaVita HealthCare currently has a Forward P/E ratio of 8.9. This represents a discount compared to its industry average Forward P/E of 18.1.
It is also worth noting that DVA currently has a PEG ratio of 0.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.78 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 59, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today
In the latest trading session, DaVita HealthCare (DVA - Free Report) closed at $111.01, marking a -3.23% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.34%. Meanwhile, the Dow experienced a drop of 0.94%, and the technology-dominated Nasdaq saw an increase of 0.16%.
Shares of the kidney dialysis provider have depreciated by 1.67% over the course of the past month, underperforming the Medical sector's gain of 0.82%, and the S&P 500's gain of 1.19%.
The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is expected to report EPS of $3.34, up 49.11% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $3.53 billion, indicating a 6.99% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $10.52 per share and a revenue of $13.55 billion, indicating changes of +8.68% and 0%, respectively, from the former year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. DaVita HealthCare is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, DaVita HealthCare currently has a Forward P/E ratio of 8.9. This represents a discount compared to its industry average Forward P/E of 18.1.
It is also worth noting that DVA currently has a PEG ratio of 0.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The average PEG ratio for the Medical - Outpatient and Home Healthcare industry stood at 1.78 at the close of the market yesterday.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 59, finds itself in the top 25% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.